Therapeutics and mild cognitive impairment: Current status and future directions

Alzheimer Disease and Associated Disorders

Volumn 17, Issue SUPPL. 2, 2003, Pages

  Thal, Leon J ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA TOCOPHEROL; AMYLOID BETA PROTEIN; APOLIPOPROTEIN E4; CELECOXIB; CHOLINE ACETYLTRANSFERASE; CHOLINESTERASE INHIBITOR; CONJUGATED ESTROGEN; CYCLOOXYGENASE 1 INHIBITOR; CYCLOOXYGENASE 2 INHIBITOR; CYTOKINE; DONEPEZIL; ESTRADIOL; ESTROGEN; ESTROGEN RECEPTOR; INDOMETACIN; MONOAMINE OXIDASE INHIBITOR; NAPROXEN; NEUROTRANSMITTER; NONSTEROID ANTIINFLAMMATORY AGENT; PLACEBO; ROFECOXIB; SELEGILINE;

ALZHEIMER DISEASE; BRAIN LEVEL; BRAIN SIZE; CELL ACTIVATION; CHOLINERGIC ACTIVITY; CLINICAL TRIAL; COGNITIVE DEFECT; COMPLEMENT ACTIVATION; CONFERENCE PAPER; DISEASE SEVERITY; DRUG EFFECT; DRUG EFFICACY; DRUG SAFETY; ESTROGEN ACTIVITY; ESTROGEN THERAPY; FOLLOW UP; FUNCTIONAL ASSESSMENT; GINKGO BILOBA; HIPPOCAMPUS; HUMAN; INSTITUTIONALIZATION; MENTAL HEALTH; MICROGLIA; MORTALITY; NERVE CELL LESION; NERVE CELL NECROSIS; NERVE DEGENERATION; NEUROPATHOLOGY; NUCLEAR MAGNETIC RESONANCE IMAGING; OUTCOMES RESEARCH; PRIORITY JOURNAL; PROTEIN FUNCTION; RATING SCALE; SYMPTOM;

EID: 0038647792     PISSN: 08930341     EISSN: None     Source Type: Journal    
DOI: 10.1097/00002093-200304002-00012     Document Type: Conference Paper

References (9)

1. Aisen PS, Davis KL, Berg JD, et al. A randomized controlled trial of prednisone in Alzheimer's disease. Alzheimer's Disease Cooperative Study. Neurology 2000;54:588-93.
2. Asthana S, Craft S, Baker LD, et al. Cognitive and neuroendocrine response to transdermal estrogen in postmenopausal women with Alzheimer's disease: results of a placebo-controlled, double-blind, pilot study. Psychoneuroendocrinology 1999;24:657-77.
3. Henderson VW, Paganini-Hill A, Miller BL, et al. Estrogen for Alzheimer's disease in women: randomized, double-blind, placebo-controlled trial. Neurology 2000;54:295-301.
4. Mulnard RA, Cotman CW, Kawas C, et al. Estrogen replacement therapy for treatment of mild to moderate Alzheimer disease: a randomized controlled trial. Alzheimer's Disease Cooperative Study. JAMA 2000;283:1007-15.
5. Rogers J, Kirby LC, Hempelman SR, et al. Clinical trial of indomethacin in Alzheimer's disease. Neurology 1993;43:1609-11.
6. Sano M, Ernesto C, Thomas RG, et al. A controlled trial of selegiline, alpha-tocopherol, or both as treatment for Alzheimer's disease. The Alzheimer's Disease Cooperative Study. N Engl J Med 1997;336:1216-22.
7. Scharf S, Mander A, Ugoni A, Vajda F, Christophidis N. A double-blind, placebo-controlled trial of diclofenac/misoprostol in Alzheimer's disease. Neurology 1999;53:197-201.
8. Wang PN, Liao SQ, Liu RS, et al. Effects of estrogen on cognition, mood, and cerebral blood flow in AD: a controlled study. Neurology 2000;54:2061-6.
9. Weggen S, Eriksen JL, Das P, et al. A subset of NSAIDs lower amyloidogenic Abeta42 independently of cyclooxygenase activity. Nature 2001;414:212-6.